Drugs / CUG252
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05866861 | Apr 2023 → Apr 2025 | systemic lupus erythematosus | Cugene Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05328557 | Nov 2021 → Aug 2022 | systemic lupus erythematosus | Cugene Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-09-18 | Cugene Inc. | Regulatory Cugene Receives FDA Approval for Phase 1a Healthy Volunteer Study of CUG252, a Treg-Selective Long-Acting IL-2 cugene.com ↗ |
| 2020-06-18 | Cugene Inc. | Results Cugene Presents Preclinical Data on CUG252 at the European E-Congress of Rheumatology (EULAR) 2020 cugene.com ↗
CUG252 shows a promising best-in-class profile among IL-2 variants, offering superior Treg selectivity while maintaining potency comparable to wild-type IL-2. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-18 | Cugene Inc. | Cugene Advances its Study of CUG252 to Phase1b, Recruiting Patients with Mild-to-Moderate SLE cugene.com ↗ |
| 2021-09-18 | Cugene Inc. | Cugene Receives FDA Approval for Phase 1a Healthy Volunteer Study of CUG252, a Treg-Selective Long-Acting IL-2 cugene.com ↗ |
| 2020-06-18 | Cugene Inc. | Cugene Presents Preclinical Data on CUG252 at the European E-Congress of Rheumatology (EULAR) 2020 cugene.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUG252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05328557 ↗ |
| Action | Inhibit | “reducing undesired IL-2 activity” NCT05866861 ↗ |
| Route | Subcutaneous | “CUG252 will be administered by subcutaneous (SC) injection” NCT05328557 ↗ |